Eli Lilly and Company
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$3.2B
Doctors Paid
6,870
Transactions
120,680
2024 Total
$649.6M
Payment Breakdown by Category
Research$3.1B (98.3%)
Consulting$20.4M (0.6%)
Travel$5.1M (0.2%)
Royalty/License$879,588 (0.0%)
Food & Beverage$693,175 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.1B | 85,462 | 98.3% |
| Consulting Fee | $20.4M | 6,790 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16.7M | 1,385 | 0.5% |
| Travel and Lodging | $5.1M | 13,524 | 0.2% |
| Grant | $4.6M | 56 | 0.1% |
| Charitable Contribution | $4.5M | 10 | 0.1% |
| Royalty or License | $879,588 | 20 | 0.0% |
| Food and Beverage | $693,175 | 13,288 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $301,000 | 2 | 0.0% |
| Education | $84,834 | 143 | 0.0% |
Payments by Type
Research
$3.1B
85,462 transactions
General
$53.3M
35,218 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | $239.0M | 240 | 2,260 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | $95.7M | 204 | 1,011 |
| A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | $89.4M | 22 | 199 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | $80.9M | 147 | 851 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | $70.6M | 151 | 476 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | $70.1M | 200 | 705 |
| ANTI-AMYLOID TREATMENT IN ASYMPTOMATIC ALZHEIMERS DISEASE -A4 STUDY | $60.0M | 61 | 1,241 |
| A PHASE 1/2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | $52.8M | 1 | 358 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | $51.3M | 48 | 351 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | $43.7M | 71 | 449 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | $42.6M | 114 | 1,657 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | $38.3M | 200 | 711 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | $37.5M | 72 | 907 |
| ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | $36.2M | 13 | 183 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | $33.7M | 155 | 2,404 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | $33.5M | 92 | 1,035 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | $30.5M | 79 | 774 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | $29.3M | 52 | 300 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA | $28.7M | 74 | 595 |
| A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | $27.2M | 53 | 468 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | $26.8M | 211 | 1,161 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | $23.1M | 61 | 473 |
| A PHASE 1 STUDY OF ORAL LOXO-292 IN ADULT PATIENTS WITH ADVANCED SOLID TUMORS HARBORING RET ALTERATIONS | $21.5M | 0 | 136 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | $19.4M | 105 | 720 |
| A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY | $19.2M | 52 | 400 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 3 STUDY OF BARICITINIB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | $18.9M | 115 | 1,061 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | $17.4M | 116 | 730 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | $16.7M | 41 | 249 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | $16.6M | 58 | 926 |
| A MULTIPLE-DOSE STUDY TO INVESTIGATE THE BIOEQUIVALENCE OF ORFORGLIPRON (LY3502970) CAPSULES AND ORFORGLIPRON TABLETS IN PARTICIPANTS WITH OBESITY OR OVERWEIGHT WHO ARE OTHERWISE HEALTHY. | $16.2M | 0 | 6 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Marschall Runge, Md, MD | Internal Medicine | Ann Arbor, MI | $2.2M | $0 |
| Dr. Jerome Barakos, M.d, M.D | Diagnostic Radiology | San Francisco, CA | $1.8M | $0 |
| Dr. Derk Purcell, M.d, M.D | Diagnostic Radiology | San Francisco, CA | $1.7M | $0 |
| Blair Brengle, Md, MD | Family Medicine | Indianapolis, IN | $1.7M | $0 |
| Dr. Barry Heller, M.d, M.D | Emergency Medicine | Long Beach, CA | $1.5M | $0 |
| Dr. Corey Hebert | Pediatrics | Gretna, LA | $1.4M | $0 |
| Camilla Lindan, Md, MD | Diagnostic Radiology | San Francisco, CA | $1.1M | $0 |
| Dr. Jason Morris, Md, MD | Family Medicine | Lake Charles, LA | $1.1M | $0 |
| Dr. Yucai Wang, Md, Phd, MD, PHD | Student in an Organized Health Care Education/Training Program | Rochester, MN | $1.0M | $0 |
| Dr. Erik Gaensler, Md, MD | Diagnostic Radiology | Walnut Creek, CA | $827,559 | $0 |
| Philip Robinson, Md, MD | Infectious Disease | Newport Beach, CA | $803,271 | $0 |
| Mr. Alan Dandrea, Md, MD | Pediatric Hematology-Oncology | Boston, MA | $777,500 | $0 |
| Jorge Castillo, Md, MD | Hematology | Boston, MA | $768,162 | $0 |
| Mrs. Lilia Roque-Guerrero, Md, MD | Pediatrics | Miami, FL | $754,747 | $0 |
| Robert Laningham, Md, MD | Family Medicine | Conroe, TX | $752,036 | $0 |
| David Schultz, M.d, M.D | Family Medicine | Evansville, IN | $733,213 | $0 |
| Dr. Awawu Igbinadolor, M.d, M.D | Adolescent Medicine | Monroe, NC | $694,884 | $0 |
| Jason Begue, Md, MD | Emergency Medicine | Birmingham, AL | $629,913 | $0 |
| Dr. Nader Sobh, D.o, D.O | Family Medicine | Los Angeles, CA | $619,606 | $0 |
| Tracey Mclaughlin, Md, MD | Endocrinology, Diabetes & Metabolism | Stanford, CA | $604,602 | $0 |
| Dr. Stephen Schleicher, M.d, M.D | MOHS-Micrographic Surgery | Sugarloaf, PA | $604,188 | $0 |
| Pasi Antero Janne, Md Phd, MD PHD | Medical Oncology | Boston, MA | $590,569 | $0 |
| Mark Kutner, Md, MD | Internal Medicine | Miami, FL | $569,817 | $0 |
| Dr. Anuj Malik, Md, MD | Internal Medicine | Tulsa, OK | $557,607 | $0 |
| Dr. Ramon Rodriguez-Cruz, Md, MD | Neurology | Orlando, FL | $555,423 | $0 |
About Eli Lilly and Company
Eli Lilly and Company has made $3.2B in payments to 6,870 healthcare providers, recorded across 120,680 transactions in the CMS Open Payments database. In 2024, the company paid $649.6M. The top product by payment volume is TALTZ ($64.5M).
Payments were distributed across 171 medical specialties. The top specialty by payment amount is Internal Medicine ($28.1M to 1,050 doctors).
Payment categories include: Food & Beverage ($693,175), Consulting ($20.4M), Research ($3.1B), Travel & Lodging ($5.1M), Royalties ($879,588).
Eli Lilly and Company is associated with 5 products in the CMS Open Payments database, including TALTZ, CYRAMZA, and HUMALOG.